Enanta Pharmaceuticals EBIT

Enanta Pharmaceuticals (ENTA) currently reports a EBIT of $-53M as of June 2026. That compares with $-84M in the prior-year period — up 36.4% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Enanta Pharmaceuticals's EBIT history and peer comparisons.

Enanta Pharmaceuticals's EBIT increased from $-84M to $-53M — a 36.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enanta Pharmaceuticals's EBIT of $-53M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Enanta Pharmaceuticals reported $-53M in EBIT as of June 2026. That compares with $-84M in the prior-year period — up 36.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-53M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Enanta Pharmaceuticals, and consider following ENTA for alerts when major investors trade the stock.